SEC Form 4 · accession 0001613377-18-000012
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Pascale
Officer — CFO
Period of report
Jul 18, 2018
Accepted (ET)
Jul 19, 2018 · 12:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to buy Common StockF1 | $0.31 | Jul 18, 2018 | A | 53,763 | A | Jul 18, 2018 | Jul 18, 2028 | Common Stock | 53,763 | 53,763 | D |
Explanation of responses
- F1This option is being issued to senior management in exchange for a voluntary 40% deferral in salary.